|Mr. Adrian Adams||CEO & Director||6.49M||N/A||1951|
|Mr. Andrew I. Koven||Pres & Chief Bus. Officer||5.02M||N/A||1958|
|Mr. Mark A. Glickman||Chief Commercial Officer||1.09M||N/A||1966|
|Dr. James Patrick Tursi M.D.||Chief Medical Officer||1.12M||N/A||1965|
|Mr. Michael Kaseta||Interim CFO & Corp. Controller||N/A||N/A||N/A|
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization. It also markets Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome; Proferrin, an iron supplement; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria. In addition, it commercializes Yosprala for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.
Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 8.